Free Trial
NASDAQ:LXEO

Lexeo Therapeutics Q4 2024 Earnings Report

Lexeo Therapeutics logo
$3.68 +0.01 (+0.27%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$3.59 -0.09 (-2.45%)
As of 04/25/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexeo Therapeutics EPS Results

Actual EPS
-$0.78
Consensus EPS
-$0.87
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Lexeo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lexeo Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 24, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Lexeo Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Lexeo Therapeutics Earnings Headlines

Trump’s tariffs just split the AI market in two
Trump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying on cheap foreign hardware—just saw their costs shoot through the roof. For the other group of AI companies, they were just handed a massive competitive advantage. Make no mistake, AI as a whole is still a game-changer for the global economy. But within the AI sector, Trump’s tariffs have created a huge divergence.
Lexeo Therapeutics price target lowered to $22 from $25 at Chardan
See More Lexeo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email.

About Lexeo Therapeutics

Lexeo Therapeutics (NASDAQ:LXEO) operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

View Lexeo Therapeutics Profile

More Earnings Resources from MarketBeat